Oral-B

News and Video Search Results

News coverage

Global Peptide Synthesis Market Analysis and Outlook 2024: Competitive Analysis of Leading Market Players, Product Developments, Key Financial and Segmental Revenues

GlobeNewswire 18 Apr 2024

Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Peptide Synthesis: Global Markets 2023-2028" report has been added to *..

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
GlobeNewswire 18 Apr 2024
Fungal Keratitis Treatment Market Size Projections Exhibit a CAGR of 5.1%, Likely to Attain a Value of USD 1.48 Billion by 2033
GlobeNewswire 18 Apr 2024
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire 18 Apr 2024
Ress Life Investments A/S: Ress Life Investments A/S publishes portfolio composition for Q1 2024
GlobeNewswire 17 Apr 2024

0 shares 1 views

You might like

Oral-B media coverage

Hunt School of Dental Medicine Working With Local Dentists for Early Diabetes Detection, Thanks to a Grant Partnership

Accesswire 17 Apr 2024

*EL PASO, TX / ACCESSWIRE / April 17, 2024 / *For El Paso residents, a visit to the dentist may involve a conversation about more..

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
GlobeNewswire 17 Apr 2024
ContextLogic Urges Stockholders to Vote FOR the Value Maximizing Transaction with Qoo10 TODAY
GlobeNewswire 17 Apr 2024
Italian Brands Shine Bright with Cutting-Edge Dental & Technological Innovations at IDEM 2024ITA-Logo.jpg
Media OutReach 17 Apr 2024
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
GlobeNewswire 17 Apr 2024

Advertisement

More coverage

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

GlobeNewswire 17 Apr 2024

· *Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated..

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
GlobeNewswire 17 Apr 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm
GlobeNewswire 17 Apr 2024
US court rejects a request by tribes to block $10B energy transmission project in Arizona
SeattlePI.com 17 Apr 2024
Panbela Announces Transfer to OTCQB Market
GlobeNewswire 16 Apr 2024